Brain metastases affect a significant percentage of patients with advanced extracranial
malignancies. Yet, the incidence of brain metastases remains poorly described, largely due …

An estimated 20% of all patients with cancer will develop brain metastases, with the majority
of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma …

Current cancer immunotherapy [eg, immune checkpoint blockade (ICB)] only benefits small
subsets of patients, largely due to immunosuppressive tumor microenvironment (TME). In …

A recent meeting was held on March 22, 2019, among the FDA, clinical scientists,
pharmaceutical and biotech companies, clinical trials cooperative groups, and patient …

Colorectal cancer (CRC) is a common malignancy worldwide. In CRC patients, metastases
are the main cause of cancer-related mortality. In a group of metastatic CRC patients, the …

Because of improvements in the treatment of patients with metastatic breast cancer, the
development of brain metastases (BM) has become a major limitation of life expectancy and …

Objectives: Common origins for brain metastases (BMs) are melanoma, lung, breast, and
renal cell cancers. BMs account for a large share of morbidity and mortality caused by these …

Brain tumors remain one of the most difficult tumors to treat and, depending on the
diagnosis, have a poor prognosis. Of brain tumors, glioblastoma (GBM) is the most common …

Metastatic tumours involving the brain overshadow primary brain neoplasms in frequency
and are an important complication in the overall management of many cancers. Importantly …

Background Patients with breast cancer are classified as having cells that over‐express the
human epidermal growth factor receptor 2 (known as HER2‐positive) or not (HER2 …